Amyloid beta (AB) peptide has a central role in the neurodegeneration of Alzheimer's disease (AD). Immunization of AD transgenic mice with AB-42 peptide reduces both the spatial memory impairments and AD-like neuropathologic changes.
Therapeutic immunization with AB in patients with AD was shown to be effective in reducing AB deposition (1). The AB deposition and aggregation is an early event in AD neuropathology, suggesting the hypothesis that AB gene vaccination would be a promising solution to reverse and prevent progressive neuropathologic change by stimulating the host immune system to recognize and target AB, thereby clearing and/or preventing the deposition of AB plaques in brain. In fact, active immunization with synthetic AB (1-42) peptide has been shown to be effective in a mouse models (2). At present, clinically relevant biomarkers used for AD diagnosis in cerebrospinal fluid (CSF) are amyloid B (AB) peptides 1-42and tau proteins (3). Antibodies against AB-42 and other isoforms have been extensively used in AD research in mouse models and as well as for dection of AB in humans (4,5) by Westren/immunoblotting and by CHIP methods the anti-AB42 and other related AB antibodies may be a good source for the rapid AB profiling of patients suspected of having AD.
Novus Biologicals offers Abeta 42 reagents for your research needs including:
